Thus, AMPK activation by obestatin does not act as a negative regulator of mTOR, which is in clear contrast to other anabolic inputs, such as insulin in DMD myotubes (Figure 4D). The gene discussed is PRKAA2; the disease is Duchenne muscular dystrophy.